Mixed Hormone Receptor (ER+/PR- Or ER-/PR+) Breast Cancer Prognosis
4.7 (576) · $ 19.99 · In stock
Detailed information on mixed hormone receptor (ER+/PR- or ER-/PR+) breast cancer prognosis, based on the latest scientific studies.
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative
Phenotypic discordance between primary and metastatic breast
Heterogeneity in hormone-dependent breast cancer and therapy
Combined quantitative measures of ER, PR, HER2, and KI67 provide
Foods To Eat And Avoid For ER-/PR+ Patients And Survivors
Novartis breast cancer drug meets trial goal; Eisai, Merck's
Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen
Hormone- and HER2-receptor assessment in 33,046 breast cancer
Challenges in Treating Estrogen Receptor-Positive Breast Cancer
Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using
Yale Cancer Center Study Shows Immunotherapy Drug Combination
Frontiers The Prognosis of Single Hormone Receptor-Positive
The Clinical and Biological Significance of Estrogen Receptor-Low
Androgen and oestrogen receptor co-expression determines the
IJMS, Free Full-Text
